Gene

FGFR2

fibroblast growth factor receptor 2

Explore in graph →CI-GENE-00001925HGNC:3689 ENSG00000066468 NCBI 2263 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (69)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–50 of 69 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF Mutation + FGFR2 Fusion + MAP2K1 MutationBRAF FGFR2 MAP2K11
(diagnostic)	Multinodular and Vacuolated Neuronal TumorALIAS

Cohorts

Alteration frequency by cohort (114)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved114 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
MSK-IMPACT and MSK-ACCESS Mixed Cohort (MSK, Nat Commun 2021) msk_access_2021	unmapped	Ssm	34	1,446

Literature

Linked publications (12)

25 per page, newest first.

pubmedPublishedShowing 1–12 of 12 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
· Lancet Oncol · 2020 · PMID 32203698 · validated civic_curation pubmed
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
· Lancet Gastroenterol Hepatol · 2021 · PMID 34358484 · validated civic_curation pubmed
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
· J Clin Oncol · 2018 · PMID 29182496 · validated civic_curation pubmed
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

FGFR2 Amplification8
(prognostic)	Malignant Gastric Neoplasm	Prognostic	B	Supports Poor Outcome	4	submitted	EID6458 Among 80 patients, FGFR2 amplification was observed in seven cases (11.5%). Patients with FGFR2 amplification had significantly shorter overall survival (OS) than did those without FGFR2 amplification… (full text at CIViC) PMID 26254407 · Shoji et al., 2015 · Open in CIViC	civic
Dovitinib	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	2	accepted	EID1605 Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11… (full text at CIViC) PMID 23658459 · André et al., 2013 · Open in CIViC	civic
Erdafitinib	Malignant Gastric Neoplasm	Predictive	D	Supports Sensitivity Response	2	submitted	EID7953 Xenograft models of SNU-16 human gastric cancer cell lines with FGFR2 amplifications were treated with JNJ-42756493 (erdafitinib). A dose dependent reduction in tumor volume was observed with treatme… (full text at CIViC) PMID 28341788 · Perera et al., 2017 · Open in CIViC	civic
Fexagratinib	Gastric CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID1990 Nine patients with FGFR2-amplified gastroesophageal cancer were treated with AZD4547. Of these 9 patients, 3 showed confirmed responses to AZD4547. Median progression-free survival was 6.6 months (ra… (full text at CIViC) PMID 27179038 · Pearson et al., 2016 · Open in CIViC	civic
Futibatinib	Triple-Negative Breast CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	2	submitted	EID11648 In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC) PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC	civic
〃	Gastric Adenocarcinoma	Predictive	C	Supports Sensitivity Response	1	submitted	EID11637 In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC) PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC	civic
Ponatinib	Malignant Gastric Neoplasm	Predictive	D	Supports Sensitivity Response	3	submitted	EID8062 In a panel of 14 cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon) and containing FGFRs dysregulated by a variety of mechanisms, ponatinib inhibited… (full text at CIViC) PMID 22238366 · Gozgit et al., 2012 · Open in CIViC	civic
Sorafenib	Gastric Adenocarcinoma	Predictive	D	Supports Sensitivity Response	2	submitted	EID13276 Three FGFR2-amplified gastric cancer cell lines showed submicromolar sensitivity to sorafenib in growth-inhibition assays: HSC-43, HSC-39, and KATOIII had IC50 values of 0.8, 0.6, and 0.4 μM, respecti… (full text at CIViC) PMID 22890726 · Arao et al., 2013 · Open in CIViC	civic

FGFR2 Fusion2
Erdafitinib	Cholangiocarcinoma	Predictive	B	Supports Sensitivity Response	3	submitted	EID10406 Phase I dose-escalation cohort of patients with advanced solid tumors in which antineoplastic therapy (NCT01703481) was no longer effective, using pan-FGFR inhibitor erdafitinib (JNJ-42756493). Among … (full text at CIViC) PMID 31088831 · Bahleda et al., 2019 · Open in CIViC	civic
〃	Bladder Urothelial Carcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID10404 Phase I dose-escalation cohort of patients with advanced solid tumors in which antineoplastic therapy (NCT01703481) was no longer effective using pan-FGFR inhibitor JNJ-42756493. Among 2 urothelial ca… (full text at CIViC) PMID 31088831 · Bahleda et al., 2019 · Open in CIViC	civic

FGFR2 Mutation7
(prognostic)	Malignant Endometrial NeoplasmCURATED_BROADER	Prognostic	B	Supports Poor Outcome	2	submitted	EID6444 patients with FGFR2 mutations had a much higher incidence of progression (32/125, 26%) whereas among those with wild type where only (120/848,14%) displayed incidences of progression. The mutated FGFR… (full text at CIViC) PMID 28314589 · Jeske et al., 2017 · Open in CIViC	civic
Dovitinib + FulvestrantCombination	Malignant Endometrial NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID6457 Treatment of cell lines harboring FGFR2 mutations with dovitinib 0.5 mmol/L for 72 hours resulted in a significant decrease in cell viability of AN3CA (37.80%) and MFE-296 (53.14%). Conversely, in cel… (full text at CIViC) PMID 24448819 · Eritja et al., 2014 · Open in CIViC	civic
Erdafitinib	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	3	submitted	EID10375 Phase I dose-escalation cohort (NCT01703481) of patients with advanced solid tumors in which antineoplastic therapy was no longer effective using pan-FGFR inhibitor erdafitinib (JNJ-42756493). 1 chola… (full text at CIViC) PMID 31088831 · Bahleda et al., 2019 · Open in CIViC	civic
〃	Cholangiocarcinoma	Predictive	C	Does Not Support Sensitivity Response	3	submitted	EID10398 Phase I dose-escalation cohort (NCT01703481) of patients with advanced solid tumors in which antineoplastic therapy was no longer effective using pan-FGFR inhibitor JNJ-42756493. 2 cholangiocarcinoma … (full text at CIViC) PMID 31088831 · Bahleda et al., 2019 · Open in CIViC	civic
Infigratinib	Cholangiocarcinoma	Predictive	B	Supports Sensitivity Response	4	accepted	EID5912 Eight patients with cholangiocarcinoma haboring FGFR2 mutations received BGJ398. No response was observed, but one tumor showed a 23% reduction in size. Water fall plot of this article showed 5 patie… (full text at CIViC) PMID 29182496 · Javle et al., 2018 · Open in CIViC	civic
〃	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID1912 Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Among three patients with cholangiocarcinoma and FGFR2 aberrations (2 fusions, 1 mutation), all three had stable diseas… (full text at CIViC) PMID 27870574 · Nogova et al., 2017 · Open in CIViC	civic
Ponatinib	Malignant Endometrial NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID1236 Preclinical study in endometrial cancer cell lines (MFE-296, AN3CA, MFE-280 and Ishikawa). In cell proliferation assays, the three FGFR2 mutant cell lines were more sensitive to the pan-FGFR inhibitor… (full text at CIViC) PMID 26574622 · Kim et al., 2016 · Open in CIViC	civic

FGFR2 N549H2
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID7510 In an in vitro kinase study, the recombinant FGFR2 N549H mutant kinase demonstrated sensitivity to bosutinib treatment at concentrations of 1μM and 10μM (activity %: 32 and 3) when compared to wild ty… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID7511 In an in vitro kinase study, the recombinant FGFR2 N549H mutant kinase demonstrated sensitivity to dasatinib treatment at concentrations of 1μM and 10μM (activity %: 6 and -1) when compared to wild ty… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC	civic

FGFR2 Overexpression7
(prognostic)	Papillary Renal Cell Carcinoma	Prognostic	B	Supports Poor Outcome	4	submitted	EID6454 Only 12/118(10.2%) of patients with type I papillary renal cell carcinoma expressed FGFR2 whereas 37/96 (38.5%) patients with type II papillary renal cell carcinoma(P=0.001). In addition, FGFR2 expre… (full text at CIViC) PMID 27379982 · Tsimafeyeu et al., 2017 · Open in CIViC	civic
〃	Hepatocellular Carcinoma	Prognostic	B	Supports Poor Outcome	4	submitted	EID6456 Patients with high FGFR2 expression had an overall survival rate of 72.2,40.6% at 1,3 years (p<0.05) and those with low FGFR2 expression had a 1,3 year survival rate of 92.0,82.8% (p<0.05). The diseas… (full text at CIViC) PMID 20798558 · Harimoto et al., 2010 · Open in CIViC	civic
〃	Rectal CarcinomaALIAS	Prognostic	B	Supports Poor Outcome	3	submitted	EID6459 FGFR2 over-expression was observed in 75.9 % (n = 107)of the 141 eligible patients and was correlated with perineural invasion (P = 0.005) and inferior tumor regression grading (TRG) (P = 0.009). On u… (full text at CIViC) PMID 26831663 · Yoon et al., 2016 · Open in CIViC	civic
〃	Hepatocellular Carcinoma	Prognostic	B	Supports Poor Outcome	3	submitted	EID6460 FGFR1, -2, -3, and -4 were expressed in 5.3%, 11.1%, 3.8%, and 52.7% of HCCs, respectively. Among the development set of 153 patients, FGFR2 positivity in HCC was associated with a significantly short… (full text at CIViC) PMID 25834803 · Lee et al., 2015 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Prognostic	D	Supports Poor Outcome	2	submitted	EID6466 It is clear that patients with FGFR2/Plcγ1/Grb2 relative concentrations as: high/high/low have the poorest prognosis whilst those having FGFR2/Plcγ1/Grb2 as: low/low/high drastically enhances the prog… (full text at CIViC) PMID 26693065 · Timsah et al., 2015 · Open in CIViC	civic
Erdafitinib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	2	submitted	EID7832 Study compares JNJ-42756493 (erdafitinib) treatment of colorectal cancer cell lines with and without FGFR2 overexpression. Overexpression determined by fold increase of FGFR2 mRNA compared to HPRT. … (full text at CIViC) PMID 26675289 · Verstraete et al., 2015 · Open in CIViC	civic
Rogaratinib	Malignant Colon Neoplasm	Predictive	D	Supports Sensitivity Response	3	submitted	EID7830 Rogaratinib (BAY 1163877) treatment was tested in vivo in a cell line-derived model of NCI‐H716 human colon cancer. This model has FGFR2 amplifications and highly elevated FGFR2 mRNA. Mice were trea… (full text at CIViC) PMID 30807645 · Grünewald et al., 2019 · Open in CIViC	civic